Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Akynzeo IV Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 192.0

    Akynzeo IV (fosnetupitant/palonosetron)

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 192.0 alerts

    Get alerted when Policy MBP 192.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit pharmaceutical policy governing prior authorization and medical necessity criteria for Akynzeo IV for prevention of chemotherapy-induced nausea and vomiting across applicable Geisinger Health Plan lines of business.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAkynzeo IV (fosnetupitant/palonosetron)
    Policy CodePolicy MBP 192.0
    Change TypeNo material change
    Effective DateN/A
    Last ReviewFeb 17, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization; Medical Director or Designee review required for medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization duration
    requiredPrior authorization
    commercial/Medicare/CHIPLines of business
    high/mod emetogenicIndicated settings

    Coverage Criteria for Akynzeo IV

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAkynzeo IV (fosnetupitant/palonosetron)
    Policy CodePolicy MBP 192.0
    Change TypeNo material change
    Effective DateN/A
    Last ReviewFeb 17, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization; Medical Director or Designee review required for medical necessity.
    SourceLink
    On This Page
    Coverage Criteria for Akynzeo IVDose Thresholds and Coding NotesProvider Requirements and Authorization ActionsInitial Therapy — Authorization CriteriaContinuation Therapy — Renewal and Ongoing AuthorizationStep Therapy RequirementsBackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Commercial, Exchange, and CHIP - Covered when ALL of the following are met

    Akynzeo IV will be considered medically necessary when ALL criteria are met:

    Commercial/Exchange/CHIP criteria: Medical record documentation that Akynzeo is being used for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
    Commercial/Exchange/CHIP criteria: Medical record documentation of a treatment failure or contraindication to at least one NK-1 antagonist (e.g., fosaprepitant, aprepitant). Treatment failure is defined as allergy, intolerable side-effects, significant drug-drug interaction, or lack of efficacy.

    Commercial/Exchange/CHIP alternative for moderately emetogenic chemotherapy

    Or, for moderately emetogenic chemotherapy, coverage when ALL of the following are met:

    Moderately emetogenic chemotherapy criteria: Medical record documentation that Akynzeo is being used for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
    Moderately emetogenic chemotherapy criteria: Medical record documentation of a treatment failure or contraindication to palonosetron (Aloxi) AND either ondansetron (Zofran) or granisetron (Kytril). Treatment failure is defined as allergy, intolerable side-effects, significant drug-drug interaction, or lack of efficacy.

    Medicare line of business - Covered when ALL of the following are met

    Akynzeo IV will be considered medically necessary for Medicare when ALL criteria are met:

    Medicare criteria: Medical record documentation that Akynzeo is being used for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
    Medicare criteria: Medical record documentation that Akynzeo is being used for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
    Medicare criteria: Medical record documentation of a treatment failure or contraindication to a corticosteroid plus a 5-HT3 receptor antagonist (e.g., ondansetron or granisetron) OR presence of additional patient-related risk factors for chemotherapy-induced nausea and vomiting as defined by NCCN guidelines. Treatment failure is defined as allergy, intolerable side-effects, significant drug-drug interaction, or lack of efficacy.

    Eligibility and contract-specific benefit limitations and exclusions apply. Coverage determinations found in line-of-business specific benefit documents take precedence and will supersede this policy. Providers must refer to the applicable member contract and benefit documents for any additional restrictions or limits that affect coverage for Akynzeo IV.

    Dose Thresholds and Coding Notes

    Carboplatin AUC threshold
    Threshold>= 4
    ContextCarboplatin AUC greater than or equal to 4 is listed among agents considered highly emetogenic.
    UseApplies when determining need for Akynzeo IV for prevention of chemotherapy-induced nausea and vomiting with highly emetogenic regimens.
    Carmustine dose threshold
    Threshold> 250 mg/m2
    ContextCarmustine at doses greater than 250 mg/m2 is listed as a highly emetogenic antineoplastic agent.
    UseGuides classification of chemotherapy emetogenicity for Akynzeo IV coverage determinations.
    Cyclophosphamide dose threshold
    Threshold> 1500 mg/m2
    ContextCyclophosphamide at doses greater than 1500 mg/m2 is identified as highly emetogenic.
    UseUsed to determine when Akynzeo IV may be indicated for prevention of CINV with high-emetogenic regimens.
    Doxorubicin dose threshold
    Threshold>= 60 mg/m2
    ContextDoxorubicin (as part of anthracycline regimens) is included in AC combinations considered highly emetogenic; threshold for doxorubicin listed as >= 60 mg/m2 in coding thresholds.
    UseInforms classification of anthracycline-containing regimens' emetogenicity for coverage of Akynzeo IV.
    Epirubicin dose threshold
    Threshold> 90 mg/m2
    ContextEpirubicin doses greater than 90 mg/m2 are listed among dose thresholds for high emetogenic potential.
    UseHelps determine when Akynzeo IV is indicated based on regimen emetogenicity.
    Ifosfamide dose threshold
    Threshold>= 2 g/m2 per dose
    ContextIfosfamide at doses greater than or equal to 2 g/m2 per dose is included in the coding thresholds for high emetogenicity.
    UseUsed to classify chemotherapy as highly emetogenic for Akynzeo IV medical necessity decisions.

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior authorization required — review by Medical Director or Designee

    Prior authorization is required; requests will be reviewed by the Medical Director or their designee to determine medical necessity for Akynzeo IV.

    Step Therapy

    Step requirement — prior treatment failure or contraindication required

    Coverage requires documented prior treatment failure or a contraindication to specified agents before approval (see clinical criteria for required comparators and definitions of treatment failure).

    • Commercial/Exchange/CHIP: treatment failure or contraindication to at least one NK-1 antagonist (e.g., fosaprepitant, aprepitant).
    • Moderately emetogenic chemo alternative: treatment failure or contraindication to palonosetron AND either ondansetron or granisetron.
    • Medicare: treatment failure or contraindication to a corticosteroid plus a 5-HT3 RA OR presence of NCCN-defined additional patient risk factors.
    Documentation Required

    Required documentation — medical records showing indication and prior agent failure/contraindication

    Submit medical record documentation demonstrating the indication: that Akynzeo is being used to prevent acute and delayed nausea and vomiting with initial and/or repeat courses of highly or moderately emetogenic chemotherapy, and documentation of treatment failure or contraindication to the required prior agents.

    • For Commercial/Exchange/CHIP: documentation of use for prevention with highly or moderately emetogenic chemotherapy and failure/contraindication to at least one NK-1 antagonist.
    • For the moderate-emetogenic alternative: documentation of failure/contraindication to palonosetron AND either ondansetron or granisetron.
    • For Medicare: documentation of failure/contraindication to corticosteroid plus a 5-HT3 RA or documentation of NCCN-defined risk factors.
    Denial Risk

    Denial triggers — lack of required indication or prior-failure documentation

    Claims may be denied if the medical record does not document that Akynzeo is being used for the prevention of acute and delayed nausea and vomiting with initial or repeat courses of highly or moderately emetogenic chemotherapy, or if required documentation of prior treatment failure/contraindication is absent.

    • Missing documentation that the drug is for prevention of acute and delayed CINV for initial/repeat courses.
    • Missing documentation of treatment failure or contraindication to the specified prior agents per line of business criteria.

    Initial Therapy — Authorization Criteria

    Initial Therapy — Initial approval criteria and duration

    Initial approval criteria and duration

    Initial approval duration: Initial approval will be for 12 months or less if the reviewing provider feels it is medically appropriate.

    Continuation Therapy — Renewal and Ongoing Authorization

    Continuation Therapy — Authorization duration and continuation requirements

    Authorization duration and continuation requirements

    Continuation authorization: Subsequent approvals will be for an additional 12 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if the patient experiences toxicity or worsening of disease.

    Step Therapy Requirements

    Line of business / settingStep therapy requirement (prior treatment failure or contraindication)
    Commercial, Exchange, and CHIP - prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapyMedical record documentation of treatment failure or contraindication to at least one NK‑1 antagonist (e.g., fosaprepitant, aprepitant). Treatment failure = allergy, intolerable side‑effects, significant drug–drug interaction, or lack of efficacy.
    Commercial/Exchange/CHIP - alternate for moderately emetogenic chemotherapyMedical record documentation of treatment failure or contraindication to palonosetron AND either ondansetron or granisetron. Treatment failure = allergy, intolerable side‑effects, significant drug–drug interaction, or lack of efficacy.
    Medicare - prevention of acute and delayed nausea and vomiting with highly or moderately emetogenic chemotherapyMedical record documentation of treatment failure or contraindication to a corticosteroid plus a 5‑HT3 RA (e.g., ondansetron or granisetron) OR presence of additional patient‑related risk factors for CINV per NCCN. Treatment failure = allergy, intolerable side‑effects, significant drug–drug interaction, or lack of efficacy.

    Background

    Akynzeo IV is a fixed intravenous combination of fosnetupitant (the prodrug of netupitant, an NK1 receptor antagonist) and palonosetron (a 5-HT3 receptor antagonist) formulated to prevent chemotherapy-induced nausea and vomiting. The two agents act together to inhibit both acute and delayed emesis and are used as part of antiemetic regimens for patients receiving highly or moderately emetogenic cancer chemotherapy.

    Use of Akynzeo IV requires prior authorization and must be medically justified in the record as prevention of acute and delayed nausea and vomiting associated with initial or repeat courses of emetogenic chemotherapy. Documentation should demonstrate the clinical indication and, where required by line of business, prior treatment failure or contraindication to specified prior agents (see coverage criteria).

    Definitions

    Akynzeo IV — drug definition (fosnetupitant + palonosetron)
    DrugAkynzeo IV (fosnetupitant/palonosetron)
    ComponentsFosnetupitant (prodrug of netupitant, an NK1 receptor antagonist) plus palonosetron (a selective 5-HT3 receptor antagonist).
    MechanismFosnetupitant augments antiemetic activity of 5-HT3 RAs and corticosteroids; palonosetron blocks serotonin peripherally and centrally and inhibits 5-HT3/NK1 cross-talk; combined they act synergistically to inhibit chemotherapy-induced emesis.
    IndicationPrevention of acute and delayed chemotherapy-induced nausea and vomiting when used as part of antiemetic regimens for highly and moderately emetogenic chemotherapy.
    Medically Necessary — definition
    DefinitionServices rendered by a Health Care Provider that the Plan determines are appropriate for the symptoms and diagnosis or treatment of the Member's condition, provided for direct care, in accordance with current standards, not primarily for convenience, and the most appropriate level of service.
    Additional inpatient meaningWhen applied to hospitalization, member requires acute inpatient care and cannot receive safe or adequate care as an outpatient.
    ScopeUsed to determine whether Akynzeo IV use meets coverage criteria under the Plan.